Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Lymphoma, non-Hodgkin's lymphoma, adult
At NIH:  Only show trials at the NIH Clinical Center (Bethesda, Md.)
Trial Type:  All
Results 1-25 of 33 for your search:
Start Over
Autologous or Donor Cytotoxic T-Lymphocytes in Treating Patients with Epstein-Barr Virus-Positive Hematologic Malignancy
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Any age
Trial IDs: ALCI, NCI-2012-00653, 9936-ALCI, H-9936, NCT00070226, NCT00671164, NCT00062868
Methoxyamine and Temozolomide in Treating Patients with Relapsed Solid Tumors or Lymphomas
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9483, NCI-2013-00877, 130118, P121184, 13-C-0118, NCT01851369
ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ACE-LY-001, NCI-2015-00533, NCT02328014
Palifermin in Preventing Graft-versus-Host Disease in Patients with Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Prevention
Age: 18 to 70
Trial IDs: 15-C-0067, NCI-2015-00084, P131448, NCT02356159
Baricitinib in Treating Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Supportive care
Age: 18 to 99
Trial IDs: 16-C-0094, NCI-2016-00773, NCT02759731
Combination Chemotherapy and Rituximab in Treating Patients with Untreated Burkitt Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 9177, NCI-2013-00915, 100052, CDR0000669336, 10-C-0052, NCT01092182
Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients with Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma following Donor Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 283-11, NCI-2011-02733, 12C0196, NCT01431209
Natural History of Recombinant Interferon Alfa-2B or Combination Chemotherapy and Rituximab in Treating Patients with Grade I-III Lymphomatoid Granulomatosis
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Treatment
Age: 12 and over
Trial IDs: 94-C-0074, NCI-2013-01582, 940074, MB-325, NCT00018993, NCT00001379
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EAY131, NCI-2015-00054, NCT02465060
Combination Chemotherapy Plus Rituximab and Filgrastim in Treating Patients with Non-Hodgkin Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 and over
Trial IDs: 93-C-0133, NCI-2009-00817, 303, 930133, CDR0000078293, NCT00018980, T93-0023, NCT00001337
Topoisomerase I Inhibitor LMP400 and Topoisomerase I Inhibitor LMP776 in Treating Patients with Relapsed Solid Tumors or Lymphomas
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 8273, NCI-2011-02515, 100056, 10-C-0056, CDR0000662682, NCT01245192, P08394, NCT01051635
Genetically-Modified Donor T Cells in Treating Patients with Relapsed B-Cell Malignancies after Donor Stem Cell Transplant
Status: Temporarily closed
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: 10-C-0054, NCI-2013-01457, 100054, P09556, NCT01087294
Donor Stem Cell Transplant in Treating Patients with DOCK8 Deficiency
Status: Active
Phase: Phase I
Type: Treatment
Age: 8 to 40
Trial IDs: 10-C-0174, NCI-2013-01462, 100174, P10665, NCT01176006
Belinostat in Treating Patients with Metastatic or Recurrent Solid Tumors or Lymphoma That Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: 8846, NCI-2013-01474, 110060, P10739, 11-C-0060, NCT01273155
Recombinant Human Interleukin-15 in Treating Patients with Metastatic or Unresectable Cancer
Status: Temporarily closed
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-C-0113, NCI-2013-01520, 120113, P11905, NCT01572493
Romidepsin in Treating Patients with Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors with Liver Dysfunction
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9008, NCI-2012-01040, CDR0000737061, J11105, NA_00052587, NCI-2013-01545, NCT01638533
ALT-803 in Treating Patients with Advanced Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: Over 18
Trial IDs: CITN-06-ALT-803, NCI-2013-01999, CA-ALT-803-01-13, NCT01946789
Ibrutinib, Temozolomide, Etoposide, Pegylated Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Rituximab in Treating Patients with Primary Central Nervous System Lymphoma
Status: Temporarily closed
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 9577, NCI-2014-01754, 09-25-0099, 140157, 14-C-0157, 14-C-0157_9577, NCT02203526
Laboratory Treated T-cells in Treating Younger Patients with Recurrent or Refractory CD22-Expressing B-cell Malignancies
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 30
Trial IDs: 15-C-0029, NCI-2015-00102, P141608, NCT02315612
Pembrolizumab in Treating Patients with HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CITN-12, NCI-2015-01906, NCT02595866
Laboratory-Treated T Cells in Treating Patients with B-cell Lymphoma or Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 73
Trial IDs: 16-C-0054, NCI-2016-00101, P152152, NCT02659943
LMP744 in Treating Patients with Relapsed Solid Tumors or Lymphomas
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 10002, NCI-2016-00787, 162675, P10002, NCT03030417
CD30 CAR-Expressing Autologous T Lymphocytes in Treating Patients with CD30-Positive Lymphomas
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 to 73
Trial IDs: 17-C-0048, NCI-2017-00115, P152529, NCT03049449
Collection and Analysis of Stored Human Samples, Specimens, or Data from Patients on Terminated Protocols
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis
Age: 18 and over
Trial IDs: 08-C-N013, NCI-2015-01186, 04-C-0142, 08CN103, P07268, NCI-08-C-N013, NCT00904514
Cellular, Molecular, Genetic, and Genomic Biology Analysis in Tissue Samples from Patients with Hematologic Malignancies
Status: Enrolling by invitation
Phase: No phase specified
Type: Biomarker/Laboratory analysis
Age: 75 and under
Trial IDs: 04-C-0102, NCI-2013-02045, 040102, NCT00900393, NCT00923442
Start Over